Nuveen Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $25.7M | Sell |
3,419,046
-1,395,503
| -29% | -$10.5M | 0.01% | 1001 |
|
|
2024
Q3 | $36.6M | Buy |
4,814,549
+319,164
| +7% | +$2.43M | 0.01% | 818 |
|
|
2024
Q2 | $27.8M | Buy |
4,495,385
+1,875,524
| +72% | +$11.6M | 0.01% | 918 |
|
|
2024
Q1 | $13.3M | Sell |
2,619,861
-847,103
| -24% | -$4.3M | ﹤0.01% | 1426 |
|
|
2023
Q4 | $20.8M | Buy |
3,466,964
+893,624
| +35% | +$5.35M | 0.01% | 1136 |
|
|
2023
Q3 | $18.2M | Buy |
2,573,340
+1,577,857
| +159% | +$11.2M | 0.01% | 1095 |
|
|
2023
Q2 | $7.01M | Buy |
995,483
+199,184
| +25% | +$1.4M | ﹤0.01% | 1718 |
|
|
2023
Q1 | $6.64M | Sell |
796,299
-809,395
| -50% | -$6.75M | ﹤0.01% | 1732 |
|
|
2022
Q4 | $18.4M | Sell |
1,605,694
-297,127
| -16% | -$3.41M | 0.01% | 1097 |
|
|
2022
Q3 | $24M | Sell |
1,902,821
-23,013
| -1% | -$290K | 0.01% | 901 |
|
|
2022
Q2 | $20.4M | Sell |
1,925,834
-531,381
| -22% | -$5.62M | 0.01% | 1040 |
|
|
2022
Q1 | $38.8M | Buy |
2,457,215
+96,290
| +4% | +$1.52M | 0.01% | 757 |
|
|
2021
Q4 | $32.7M | Sell |
2,360,925
-68,761
| -3% | -$952K | 0.01% | 932 |
|
|
2021
Q3 | $34.9M | Sell |
2,429,686
-135,734
| -5% | -$1.95M | 0.01% | 892 |
|
|
2021
Q2 | $40.6M | Buy |
2,565,420
+61,065
| +2% | +$965K | 0.01% | 863 |
|
|
2021
Q1 | $25.5M | Buy |
2,504,355
+931,841
| +59% | +$9.48M | 0.01% | 1146 |
|
|
2020
Q4 | $11.7M | Sell |
1,572,514
-54,093
| -3% | -$403K | ﹤0.01% | 1600 |
|
|
2020
Q3 | $5.59M | Sell |
1,626,607
-60,201
| -4% | -$207K | ﹤0.01% | 1859 |
|
|
2020
Q2 | $8.04M | Sell |
1,686,808
-94,441
| -5% | -$450K | ﹤0.01% | 1634 |
|
|
2020
Q1 | $3.56M | Buy |
1,781,249
+712,751
| +67% | +$1.43M | ﹤0.01% | 1894 |
|
|
2019
Q4 | $3.69M | Buy |
1,068,498
+245,616
| +30% | +$848K | ﹤0.01% | 2145 |
|
|
2019
Q3 | $2.36M | Buy |
822,882
+4,649
| +0.6% | +$13.3K | ﹤0.01% | 2330 |
|
|
2019
Q2 | $3.1M | Buy |
+818,233
| New | +$3.1M | ﹤0.01% | 2234 |
|